Nitroso-STG-19 (Sitagliptin)

Nitroso-STG-19, also known as Sitagliptin, is a medication used to treat Type 2 diabetes. It belongs to a class of drugs called dipeptidyl peptidase-4 inhibitors and works by increasing levels of incretin hormones which in turn stimulates the pancreas to release insulin. This medication is usually taken orally and is available in tablet form. Chemically, Nitroso-STG-19 is a white to off-white, crystalline, non-hygroscopic powder. It is soluble in water and N,N-dimethylformamide, slightly soluble in methanol, very slightly soluble in ethanol and practically insoluble in hexane. Its chemical formula is C16H15F6N5O and its molecular weight is 407.3 g/mol. Nitroso-STG-19 is metabolized in the liver and excreted in the urine. It has a half-life of approximately 12.4 hours and reaches peak plasma concentrations within 1 to 4 hours after administration. It is important to note that this medication should not be used in patients with Type 1 diabetes or diabetic ketoacidosis. Common side effects of Nitroso-STG-19 include headache, runny or stuffy nose, sore throat, and stomach upset. In rare cases, it may cause pancreatitis or severe allergic reactions. Patients should be monitored closely for any signs of these complications. Overall, Nitroso-STG-19 is a valuable medication in the treatment of Type 2 diabetes when used appropriately under medical supervision.